Alzheimer's disease. Clinical practice guideline;Enfermedad de Alzheimer. Guía de práctica clínica

Neurologia Argentina

Volumn 3, Issue 2, 2011, Pages 120-137

  Allegri, Ricardo F ^a   Arizaga, Raúl L ^a   Bavec, Claudia V ^a   Colli, Liliana P ^a   Demey, Ignacio ^a   Fernández, María C ^a   Frontera, Silvina A ^a   Garau, María L ^a   Jiménez, Julio J ^a   Golimstok, Ángel ^a   Kremer, Janus ^a   Labos, Edith ^a   Mangone, Carlos A ^a   Ollari, Juan A ^a   Rojas, Galeno ^a   Salmini, Omar ^a   Ure, Jorge A ^a   Zuin, Daniel R ^a  

^a Sociedad Neurológica Argentina ^*  (Argentina)

Author keywords

Alzheimer disease; Clinical practice guideline; Dementia

Indexed keywords

ALZHEIMER DISEASE; ARGENTINA; EVIDENCE BASED MEDICINE; MEDICAL SOCIETY; PRACTICE GUIDELINE; PROFESSIONAL KNOWLEDGE; REVIEW;

EID: 79956259028     PISSN: 18530028     EISSN: 18530028     Source Type: Journal    
DOI: 10.1016/S1853-0028(11)70026-X     Document Type: Article

References (116)

1. Raz N, Lindenberger U, Rodrigue KM, Kennedy KM, Head D, Williamson A, et al. Regional brain changes in aging healthy adults: General trends, individual differences and modifiers. Cerebral Cortex. 2005;15:1676-89. (Pubitemid 41447032)
2. Drag LL, Bieliauskas LA. Contemporary Review 2009: Cognitive Aging. J Geriatr Psychiatry Neurol. 2010;23;75-93.
3. Price JL, McKeel DW Jr., Buckles VD, Roe CM, Xiong C, Grundman M, et al. Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging. 2009;30:1026-36.
4. Cummings JL. Alzheimer's disease. N Engl J Med. 2004;351:56-67.
5. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010;362:329-44.
6. Hu WT, McMillan C, Libon D, Leight S, Forman M, Lee VM-Y, et al. Multimodal predictors for Alzheimer's disease in nonfluent primary progressive aphasia. Neurology. 2010;75:595-602.
7. Alladi S, Xuereb J, Bak T, Nestor P, Knibb J, Patterson K, et al. Focal cortical presentations of Alzheimer's disease. Brain. 2007;130:2636-45. (Pubitemid 47511719)
8. Deramecourt V, Lebert F, Debachy B, Mackowiak-Cordoliani MA, Bombois S, Kerdraon O, et al. Prediction of pathology in primary progressive language and speech disorders. Neurology. 2010;74:42-9.
9. Knibb JA, Xuereb JH, Patterson K, Hodges JR. Clinical and pathological characterization of progressive aphasia. Ann Neurol. 2006;59:156-65. (Pubitemid 43042882)
10. Greene JD, Patterson K, Xuereb JH, Hodges JR. Alzheimer's disease and nonfluent progressive aphasia. Arch Neurol. 1996;53:1072-8. (Pubitemid 26340045)
11. Cummings J. Primary progressive aphasia and the growing role of biomarkers in neurological diagnosis. Ann Neurol. 2008;64:361-4.
12. Gorno-Tempini ML, Dronkers NF, Rankin DP, Ogar JM, Phengrasamy L, Rosen HJ, et al. Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol. 2004; 55:335-46. (Pubitemid 38269585)
13. Galton CJ, Patterson K, Xuereb JH, Hodges JR. Atypical and typical presentations of Alzheimer's disease: A clinical, neuropsychological, neuroimaging and pathological study of 13 cases. Brain. 2000;123:484-98. (Pubitemid 30099534)
14. Gorno-Tempini ML, Brambati SM, Ginex B, Ohar J, Marcone A, Perani D, et al. The logopenic/phonological variant of primary progressive aphasia. Neurology. 2008;71:1227-34.
15. Mesulam M-M, Wicklund A, Johnson N, Rogalski E, Liger GC, Rademaker A, et al. Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Ann Neurol. 2008;63:709-19. (Pubitemid 351945530)
16. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans. Ann Neurol. 2006;59:512-9. (Pubitemid 43358072)
17. Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, et al. Relationships between biomarkers in aging and dementia. Neurology. 2009;73:1193-9.
18. Mintun MA, Larossa GN, Sheline YI, Dence CS, Yoon Lee S, Mach RH, et al. [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446-52. (Pubitemid 44214969)
19. Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel SJ, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain. 2006;129:3035-41. (Pubitemid 44684523)
20. Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy confirmed dementia diagnoses? Arch Neurol. 2003;60:1696-702.
21. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiBPET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008;131:1630-45. (Pubitemid 351806448)
22. Strozyk D, Blennow K, White LR, Launer LJ. CSF Ax 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology. 2003;60:652-6. (Pubitemid 36246085)
23. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, et al. Cerebrospinal fluid x-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66:382-9.
24. Reisberg B. Diagnostic criteria in dementia: A comparison of current criteria, research challenges, and implications for DSM-V. J Geriatr Psychiatry Neurol. 2006;19;137-46. (Pubitemid 44154853)
25. Censo Nacional de Población, Hogares y Viviendas del año 2001, República Argentina. Disponible en: http://www.indec.mecon.ar/ webcenso/index.asp
26. United Nations, Department of Economic and Social Affairs, Population Division, Population Ageing 2006. Disponible en: www.unpopulation.org
27. U.S. Census Bureau, Global Population Profile: 2002, table A-12. Disponible en: http://www.census.gov/
28. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366:2112-7. (Pubitemid 41797645)
29. Kalaria RN, Maestre GE, Arizaga R, Friedland RP, Galasko D, Hall K, et al. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol. 2008;7:812-26.
30. Pagés Larraya F, Grasso L, Marí G. Prevalencia de las demencias del tipo Alzheimer, demencias vasculares y otras demencias del DSM-IV y del ICD-10 en la República Argentina. Rev Neurol Arg. 2004;29:148-53.
31. Arizaga RL, Gogorza RE, Allegri RF, Barman D, Morales MC, Harris P, et al. Deterioro cognitivo en mayores de 60 años en Cañuelas (Argentina). Resultados del Piloto del Estudio Ceibo (Estudio Epidemiológico Poblacional de Demencia). Rev Neurol Arg. 2005;30:83-90.
32. Allegri RF, Butman J, Arizaga RL, Machnicki G, Serrano C, Taragano FE, et al. Economic impact of dementia in developing countries: an evaluation of costs of Alzheimer-type dementia in Argentina. Int Psychogeriatr. 2007;19:705-18. (Pubitemid 47037093)
33. Abel C, Allegri RF, Arizaga RL, Baumann D, Bavec C, Caccuri R, et al. Guía de Práctica Clínica en la Enfermedad de Alzheimer. Rev Neurol Arg. 2006;31:140-4. (Pubitemid 351944918)
34. Hodges JR. Alzheimer's centennial legacy: Origins, landmarks and the current status of knowledge concerning cognitive aspects. Brain. 2006;129:2811-22. (Pubitemid 44684505)
35. McKeith IG, Cummings J. Behavioural changes and psychological symptoms in dementia disorders. Lancet Neurol. 2005;4:735-42. (Pubitemid 41457289)
36. Cummings JL. The Black Book of Alzheimer's Disease, Part 2. Primary Psychiatry. 2008;15:69-90.
37. García Alberca JM, Lara JP, González Barón S, Barbancho MA, Porta D, Berthier M, et al. Prevalencia y comorbilidad de síntomas neuropsiquiátricos en la enfermedad de Alzheimer. Actas Españolas de Psiquiatría. 2008;36:265-70.
38. Reisberg B, Franssen E, Sclan S, Kluger A, Ferris S. Stage specific incidence of potentially remediable behavioral symptoms in aging and Alzheimer's disease: a study of 120 patients using the BEHAVE-AD. Bull Clin Neurosci. 1989;54:95-112.
39. Finkel S, Costa e Silver J, Cohen G, Miller S, Sartorius N. Behavioral and psychological symptoms of dementia: A consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr. 1996;8:497-500.
40. Burns A. Misidentifications. Int Psychogeriatr. 1996;8 Suppl 3:393-7.
41. Finkel S. Behavioral and psychological symptoms of dementia. Clin Geriatr Med. 2003;19:799-824.
42. Cummings Jl, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Grnbein J. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308-14. (Pubitemid 24382728)
43. Folstein MF, Folstein SE, McHugh PR. Mini Mental State. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-98.
44. Sunderland T, Hill JL, Mellow AM, Lawlor BA, Gundersheimer J. Clock drawing in Alzheimer's disease. A novel measure of dementia severity. J Am Geriatr Soc. 1989;37:725-9. (Pubitemid 19199790)
45. Mangone CA, Grillo R, Saavedra L, Pallo V. Nuevas variables de evaluación del Test del Reloj. Vértex. 2005;16:13-9.
46. Butman J, Allegri R, Harris P, Drake M. Fluencia verbal en español. Datos normativos en Argentina. Medicina. 2000;60:561-4.
47. Gauthier L, Dehaut F, Joanette Y. The bell test: a quantitative and qualitative test for visual neglect. Intl J Neuropsychol. 1989;11:49-54. (Pubitemid 19208934)
48. Beck LH, Bransome ED Jr., Mirsky AF, Rosvold HE, Sarason I. A continuous performance test of brain damage. J Consult Psychol. 1956;20:343-50.
49. Wechsler D. Test de Inteligencia para Adultos - WAIS-III. Buenos Aires: Paidos; 2002.
50. Wechsler DA. Wechsler Memory Scale-revised. New York: Harcourt Brace Jovanivich Publishers; 1987.
51. Reitan RM. Validity of the Trail Making Test as an indication of organic brain damage. Percept Mot Skills. 1958;8:271-6.
52. Rey A. L'examen clinique en psychologie. París: Presses Universitaires de France; 1958.
53. Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test: Adult Version Manual. San Antonio, TX: The Psychological Corporation; 1987.
54. Buschke H, Fuld PA. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology. 1974;24:1019-25.
55. Rey A. Test de copie et de reproduction de mémoire de figures géométriques complexes. París: Centre de Psychologie Appliquée; 1959.
56. Allegri R, Mangone C, Rymberg S, Fernandez A, Taragano F. Spanish version of the Boston Naming Test in Buenos Aires. Clin Neuropsychol. 1997;11:416-20. (Pubitemid 28015259)
57. Howard D, Patterson K. Pyramids and palm trees. A test of semantic access from picture and words. Bury St. Edmunds: Thames Valley Publishing; 1992.
58. Cohen NJ, Squire LR. Preserved learning and retention of pattern analyzing skill in amnesia: dissociation of knowing how and knowing what. Science. 1980;210:207-10. (Pubitemid 11210996)
59. Spreen O, Benton A. Neurosensory Center Comprehensive Examination for Aphasia. Victoria: University of Victoria. Neuropsychology Laboratory; 1969, 1977.
60. De Renzi E, Vignolo LA. The token test a sensitive test to detect receptive disturbances in aphasics. Brain. 1962;85:665-78.
61. Kaplan E, Goodglass H, Weintraub S. La evaluación de la afasia y de sus trastornos relacionados. Madrid: Panamericana; 1986.
62. Benton AL, Hamsher KS, Varney NR, Spreen O. Contributions to neuropsychological assessment: a clinical manual. Nueva York: Oxford University Press; 1983.
63. Hooper HE. Hooper Visual Organization Test (VOT). Los Angeles: Western Psychologycal Services; 1983.
64. Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol. 1935;18:643-62.
65. Luria AR. The frontal lobes and the regulation of behaviour. En: Pribram KH, Luria AR, editors. Psychophysiology of the frontal lobes. New York: Academic Press; 1973.
66. Heaton RK. Wisconsin Card Sorting Test Manual. Revised and expanded. En: Osea FL. Psychological Assessment Resources, 1993.
67. Rosen GW, Mohs R, Davis JL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356-64.
68. Mangone CA, De Pascale AM, Gigena VMG, et al. Escala de Evaluación para Enfermedad de Alzheimer (ADAS). Adaptación a la lengua castellana. Confiabilidad interexaminadores en retesteo seriado. Rev Neurol Arg. 1995;20:31-42.
69. Cummings Jl, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Grnbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308-14. (Pubitemid 24382728)
70. Reisberg B. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry. 1987;48 Suppl 5:9-15. (Pubitemid 17091427)
71. Zarit SH, Todd PA, Zarit JM. Subjective burden of husbands and wives as caregivers: a longitudinal study. Gerontologist. 1986;26:260-6.
72. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An Inventory for measuring depression. Arch Gen Psychiatry. 1961;4:53-63.
73. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
74. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey MB, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiat Res. 1983;17:37-49. (Pubitemid 13123113)
75. Burns A, Folstein S, Folstein M, Brandt J. Clinical assessment of irritability, aggression and apathy in Huntington and Alzheimer's disease. J Nerv Mental Dis. 1990;178:20-6. (Pubitemid 20175040)
76. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50-5.
77. Young R, Biggs J, Zieglar V, Meyer D. A rating scale for Mania: reliability, validity, sensitivity. Br J Psychiatr. 1978;133:429-35. (Pubitemid 9006756)
78. Reisberg B, Ferris SH. A clinical rating scale for symptoms of psychosis in Alzheimer's disease. Psychopharmacology Bull. 1985;21:101-4.
79. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. The Index of ADL: A standardized measure of biological and psychosocial function. JAMA. 1963;185:914-9.
80. Lawton MP, Brody EM. Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179-186.
81. FDA. Disponible en: http://www.fda.gov
82. EMEA. Guideline on medicinal products for the treatment of Alzheimer's disease and other dementias. Disponible en: http://www.ema.europa.eu/docs/en-GB/ document-library/Scientific-guideline/2009/09/WC500003562.pdf
83. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer's disease and senile dementia, loss of neurons in the basal forebrain. Science. 1982;215:1237-9. (Pubitemid 12106486)
84. ANMAT. Disponible en: http://www.anmat.gov.ar/Medicamentos/basedat.asp
85. Abel C, Allegri RF, Arizaga RL, Baumann D, Bavec C, Caccuri R, et al. Guía de práctica clínica en la enfermedad de Alzheimer. Sociedad Neurológica Argentina. Rev Neurol Arg. 2006;31:140-4.
86. Burns A, O'Brien J. Clinical practice with antidementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol. 2006;20:732-55. (Pubitemid 44622739)
87. Howard R, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med. 2007;357:1382-92. (Pubitemid 47535593)
88. Areosa Sastre A, Sherriff F, McShane R. Memantine for dementia. The Cochrane Database of Systematic Reviews 2005; Issue 3. Art. No. CD003154. DOI: 10.1002/14651858.CD003154.pub4.
89. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2006; 25(1):CD001190.
90. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006; 25(1):CD005593.
91. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): Randomised double-blind trial. Lancet. 2004;363:2105-15.
92. Cummings JL. The Black Book of Alzheimer's Disease, Part 2. Primary Psychiatry. 2008;15:69-90.
93. Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, et al. Management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1154-66.
94. Abel C, Allegri RF, Garau L, Genovese O, Mangone CA; Consortium Argentino para el Estudio de la Demencia. Treatment of Alzheimer's Disease cognitive symptoms. Vertex. 2008;19 Suppl:39-47.
95. Agencia de medicamentos del Reino Unido. Compendio oficial de medicamentos del Reino Unido (ABPI). Disponible en: http://www.medicines.org.uk/ emc/
96. Agencia española de Medicamentos. Disponible en: https://sinaem.agemed.es
97. National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease (amended September 2007). Disponible en: http://www.nice.org.uk/guidance/TA111
98. Waldemar G, Dubois B, Emre M, Georges J, McKeith IG, Rossor M, et al. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol. 2007;14:e1-e26. (Pubitemid 46088015)
99. Health Canada. Disponible en: http://webprod.hc-sc.gc.ca/dpd-bdpp/index- eng.jsp
100. Leon J, Cheng CH, Neumann PJ. Alzheimer's disease. Care: Costs and potential savings. Health Affairs. 1998;17:206-16.
101. Neugroschl J, Sano M. Current treatment and recent clinical research in Alzheimer's disease. Mount Sinai Journal of Medicine. 2010;77:3-16.
102. Krall WJ, Sramek JJ, Cutler NR. Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease. Ann Pharmacother. 1999;33:441-50. (Pubitemid 29215811)
103. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006; Apr. 19 (2):CD003154.
104. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Möbius HJ; Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348:1333-41. (Pubitemid 36384100)
105. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291:317-24. (Pubitemid 38101604)
106. Martindale. The complete drug reference. 36th edition. Pharmaceutical Press; 2009.
107. Alvarez XA, Cacabelos R, Laredo M, Couceiro V, Sampedro C, Varela M, et al. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. Eur J Neurol. 2006;13:43-54.
108. Bae C-Y, Cho C-Y, Cho K, Hoon Oh B, Choi KG, Lee HS, et al. A double-blind, placebo controlled, multicenter study of Cerebrolysin for Alzheimer's disease. J Am Geriatr Soc. 2000;48:1566-71.
109. Panisset M, Gauthier S, Moessler H, Windisch M. Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo controlled trial with a neurotrophic agent. J Neural Transm. 2002;109:1089-104. (Pubitemid 34762347)
110. Wei Z-H, He Q-B, Wang H, Su BH, Chen HZ. Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease. J Neural Transm. 2007;114:629-34. (Pubitemid 46664058)
111. a ed. McGraw-Hill; 2006.
112. Nemeroff CHB, Kelsey JE, Newport J. Principles of psychopharmacology for mental health professionals. John Wiley & Sons, Inc; 2006. p. 283-310.
113. Gill SS, Bronskill SE, Normand SLT, Anderson GM, Sykora K, Lam K, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146:775-86. (Pubitemid 351650498)
114. Schneeweiss S, Setoguchi S, Brookhart A, Cormuth C, Wang P. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007;176:627-32. (Pubitemid 46426056)
115. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353:2335-41. (Pubitemid 41713745)
116. O'Brien JT, Burns A. Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2010; Nov 18 [Epub ahead of print]: doi 10.1177/0269881110387547; PMID 21088041.